#News: atai Life Sciences & @BeckleyPsytech have combined to form atai Beckley – Creating a global leader in psychedelic mental health therapies #mentalhealth therapies. Together, we’re accelerating innovation for those in need. Learn more: Join our

RT @C_Angermayer: I am very sad to hear that Amanda Feilding has passed away. She was a legend – and not only in the psychedelic world. W….

Q4 #Earnings highlights: Strong financial position following successful capital raise, with two Phase 2 trials underway & large Phase 2b results expected mid-2025. 🔗 #MentalHealth.

Milestone update: Enrollment complete in Ph2b trial of @BeckleyPsytech's BPL-003 for treatment-resistant depression (TRD). Results expected mid-2025. Full announcement here:

Kicking off 2025 with a strengthened leadership team: Srinivas Rao leads as sole CEO, Kevin Craig promoted to CMO, Glenn Short promoted to CSO, Gerd Kochendoerfer joins as COO. With VLS-01 & EMP-01 entering Phase 2 & BPL-003 data anticipated in Q2, we’re advancing novel.

We believe that innovation is only impactful if it’s practical. Treatments must be effective and accessible to all patients. On the Power to the Patient podcast, our Co-Founder & Co-CEO @SrinivasRao and @Brandonhli discuss: TRD, SAD, psychedelics & our pragmatic, patient-focused.

Q3 #Earnings update: IND cleared for VLS-01 with Phase 2 in TRD initiating around YE’24. Also on track for Phase 2 study of EMP-01 in SAD. Exciting momentum as we drive mental health innovation forward. Full press release:

Every day, over 300 million people face the struggle of depression. 1 in 3 find no relief in current treatment options. For those living with treatment-resistant depression, hope feels out of reach. We're proud to share the next video in our #OneBillionPeople series, highlighting

Excited to head to Boston for #CNSSummit2024 next week! Our co-founder @SriniGRao and SVP Kevin Craig will discuss advancements in science, the potential of psychedelics in #mentalhealth, and how atai prioritizes patient needs in our clinical trials. If you’re attending, let us.

Tomorrow is Mental Health Awareness Day – an opportunity to raise awareness about mental health and provide support to those in need. Our team is taking the day off to prioritize our own mental health. That’s why, today, we are sharing the first video in our new series, one.

Overdose deaths declined by 3% from 2022 to 2023, the first drop since 2018 (CDC). The work is far from done – as over 100,000 lives were lost last year. At atai, we continue to work towards new options #EndOverdose #IOAD2024 #MentalHealth.

A must listen: atai’s Dr. Jennifer Tippett on The #PsychedelicTherapy Podcast with @eamonarmstrong , discussing psychological support within psychedelic treatment and more.

What can we do to help people, particularly women, make sure they are supported so they don’t need to take a #mentalhealth leave from work? Jennifer Birdsall explores this and more in the recent @Fortune piece.

Earlier this week we announced positive topline results from the Phase 1b trial of VLS-01 for patients with TRD. Read our co-CEO @SriniGRao's blog to learn how DMT works and what this could mean for patients

Our team has made excellent progress this quarter on our #clinical programs. ✔️Announced Phase 1b results for VLS-01 (oral buccal film DMT), with a Phase 2 study in 142 patients with treatment-resistant #depression expected to initiate around year end. See our new corporate

RT @flobrand: Grateful for your coverage of our VLS-01 Phase 1 results as well as our plans for progressing VLS-01 into a Phase 2 in TRD in….

Today we announced positive initial results from Phase 1b of our VLS-01 program, a proprietary oral formulation of DMT we are developing for an estimated 100 million people suffering from treatment-resistant #depression. The results support the potential of VLS-01 as

RT @flobrand: 👇Tune in!.